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Abstract 
The prostate epithelium is composed of basal (BC), luminal (LEC), and neuroendocrine (NEC) 
cells. It is unclear how many subtypes of BCs in the prostate and which subtype of BCs contains the 
main stem cell niche in the adult prostate. Here we report seven BC subpopulations according to 
their p63, cytokeratin 14 (K14) and K5 expression patterns, including 
p63-positive/K14-negative/K5-negative (p63+/K14-/K5-), p63-/K14+/K5-, p63-/K14-/K5+, 
p63+/K14+/K5-, p63+/K14-/K5+, p63-/K14+/K5+, and p63+/K14+/K5+ BCs. We generated a 
p63-CreERT2 knock-in mouse line that expresses tamoxifen-inducible Cre activity in the 
p63-expressing cells, including the prostate BCs. We then crossbred this line with ROSA26R mice, 
and generated p63-CreERT2×ROSA26R bi-genic mice harboring the Cre-activated 
β-galactosidase reporter gene. We treated these bi-genic mice with tamoxifen to mark the p63+ 
BCs at different ages or under different hormonal conditions, and then traced the lineage dif-
ferentiation of these genetically labeled BCs. We discovered that these p63+ BCs contain 
self-renewable stem cells in culture and efficiently differentiated into LECs, NECs and BCs in the 
postnatal, adult and re-generating mouse prostates. Therefore, BC population contains hetero-
geneous BCs that express different combinations of the p63, K14 and K5 differentiation markers. 
Because K14+ and K5+ BCs were previously shown to be extremely inefficient to produce LECs 
in adulthood, we propose that the p63+/K5-/K14- subpopulation of BCs contains most stem-like 
cells, especially in adult animals. 
Key words: Prostate epithelium, basal cell differentiation, p63, lineage tracing, stem cell. 
Introduction 
The prostate originates from epithelial budding 
from an intermediate region of the primitive urogen-
ital sinus, which is a hindgut derivative of the endo-
derm. Both human and murine prostate glands are 
composed of an outer layer of basal cells (BCs), which 
lie on a basement membrane, and an inner layer of 
luminal epithelial cells (LECs). The neuroendocrine 
cells (NECs) are rare in number and are scattered 
among LECs without extending to the lumen [1]. 
LECs express cytokeratin 8 (K8), K18 and androgen 
receptor (AR). BCs express K14, K5 and p63. NECs 
express synaptophysin (Syp), somatostatin and 
chromogranin A and also possess numerous rich ser-
otonin-containing granules [2]. 
Lineage tracing studies during prostate devel-
opment and homeostasis are relevant to the origin of 
prostate cancer cells. In vitro and ex vivo studies have 
suggested that subsets of BCs in adult murine prostate 
may contain pluripotent and self-renewal stem cells, 
which can be related to prostate cancer initiation [3, 4]. 
Similarly, a subset of human prostate BCs is able to 
reconstitute prostatic gland in a model system [5], and 
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tracing the cell lineage with mitochondrial DNA mu-
tation also suggests that human prostate BCs may 
contain stem cells to generate other types of epithelial 
cells in the prostate [6, 7]. However, recent prostate 
epithelial lineage-tracing studies using genetically 
manipulated mouse models have provided different 
results regarding the multi-potent capabilities of BCs 
and LECs to generate other types of epithelial cells in 
the prostate. Although the K14-positive (K14+) BCs 
were shown to be able to differentiate into other types 
of epithelial cells during postnatal prostate morpho-
genesis, genetically marked K14+ BCs in the adult 
prostate were unable to generate LECs [8, 9]. Fur-
thermore, genetically marked K5+ BCs in the prostate 
of adult mouse could produce very few, if any, LECs 
under normal physiological conditions [9, 10]. These 
findings indicate that the K14+ or K5+ BCs in the 
prostate of adult animal are unlikely the multipotent 
tissue stem cells. Furthermore, prostatic BCs in the 
adult animal have not been shown to be able to gen-
erate NECs. Hence, it remains to be addressed 
whether the prostatic BC population in the adult an-
imal contains stem cells with a full differentiation 
spectrum. 
Here, we report the identification of seven BC 
subpopulations in the mouse prostate, including the 
previously unrecognized p63+/K14-negative 
(K14-)/K5- BC subpopulation. We show that 
p63-expressing BCs contain multipotent stem cells 
that can efficiently differentiate into LECs, BCs and 
NECs during postnatal prostate morphogenesis, adult 
prostate epithelial homeostasis, and andro-
gen-stimulated prostate epithelial regeneration in the 
adult animal. 
Materials and Methods 
Mice 
The p63-CreERT2 mouse line was generated by a 
knock-in strategy illustrated in Figure 1. To construct 
the targeting vector, the genomic DNA of TC-1 mouse 
ES cells was used as PCR template for amplifying 
targeting arms. The 5’ targeting arm was amplified by 
PCR using primers 5’- gcgttaattaaCTCTTAGTCCTGG 
ACATCCGCATTGAAGT with a Pac I site and 5’- 
atagcggccgCCCCAGGTTCGTGTACTGTGGCTGT 
with a Not I site. The DNA coding CreERT2 and 
β-globin poly(A) addition-signaling sequence was 
amplified by PCR using primers 5’- atagcggccgctg 
TCCAATTTACTGACCGTACACC with a Not I site 
and 5’- 
acaggtaccCTTCGAATTCCT
CGACCAGAC with an 
Acc65 I site. These two PCR 
products were cloned into 
the targeting vector between 
Pac I and Acc65 I sites, 
which were upstream of the 
FRT-flanked PGK-neo 
cassette. The 3’-targeting 
arm was amplified by PCR 
using primers 5’- 
acgctcgagCCGGAGCAATC
AACTTTGAAGACAGTAC 
with an Xho I site and 5’- 
agcggattcGGAAAGTACCA
ACAGCAAATATCCCACA
G with an EcoR I site. The 3’ 
arm was cloned into the 
targeting vector between 
PGK-neo and HSV-tk 
cassettes. The vector was 
linearized by Pac I digestion. 
The vector was designed to 
knock in the 
CreERT2-coding sequence 
into exon 4, resulting in an 
in-frame fusion after the 
115th a.a. of p63 or the 24th 
a.a. of ∆Np63 isoform (Fig. 
 
Figure 1. Generation of the p63-CreERT2 knock-in mouse line. A. Schematic drawing of the murine p63 gene wild 
type (WT) allele and the CreERT2-pA-FRT-Neo-FRT knock-in (KI) allele. Exons (E) 3-6 are indicated in both alleles. The 5’ and 
3’ homologous regions used in the targeting vector are indicated by dotted lines between WT and KI alleles. The locations of 
the 5’ and 3’ probes used in Southern blot are indicated. The locations of primers P1, P2 and P3 used for genotype analysis are 
also indicated. B. Southern blot analysis of the WT and KI alleles. The 5’ probe-detected 12.6 and 8.1 kb fragments were 
respectively derived from the WT and KI alleles after Pst I digestion. The 3’ probe-detected 10.2 and 8.3 kb fragments were 
respectively derived from the KI and WT alleles after Acc65 I digestion. C. Genotype analysis of mouse genotypes by PCR. 
Mouse genomic DNA was used as PCR template. The 516 bp fragment was detected from the WT allele by primers P1 and P2. 
The 335 bp fragment was detected from the KI allele by primers P1 and P3. 
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1A). The TC-1 mouse ES cells were transfected with 
the vector DNA by electroporation, cultured on feeder 
cells, and selected in medium containing G418 and 
fialuridine (FIAU) as described previously [11, 12]. 
Survived individual colonies were isolated and 
screened by Southern blotting. The 5’ probe was used 
to detect the 12.6-kb and 8.1-kb fragments produced 
from the respective 5’ regions of the wild type and 
targeted alleles after Pst I digestion. The 3’ probe was 
used to detect the 8.3-kb and 10.2-kb fragments were 
produced from the respective 3’ regions of the wild 
type and targeted alleles after Acc65 I digestion (Fig. 
1B). The targeted clones were injected into C57BL/6 
blastocysts to produce chimeric mice. Male chimeric 
mice were further crossbred with female FLPeR mice 
[13] to remove the Frt-flanked PGK-neo cassette and 
simultaneously obtain the p63-CreERT2 heterozygous 
mouse line as described previously [12]. Mouse 
genotype analysis was carried out by PCR using DNA 
template prepared from a piece of ear tissue and three 
primers. Primers P1 (5’-AATGTTGGGGTGTCTGGA
TG) and P2 (5’-CAGCAGTCAGGAACAAAGAGG) 
were used to detect the 516-bp fragment of the p63 
wild type allele. Primers P1 and P3 
(5’-GCCCAAATGTTGCTGGATAG) were used to 
detect the 335-bp fragment of the p63-CreERT2 
knock-in allele (Fig. 1C). 
The ROSA26R mice harboring a Cre-activated 
expression of the β-galactosidase (β-gal) reporter gene 
[14] were obtained from the Jackson Laboratory. The 
bi-genic mice used in this study were generated by 
crossbreeding ROSA26R mice with p63-CreERT2 
mice. Animal protocols were approved by the Institu-
tional Animal Use and Care Committee at Baylor 
College of Medicine. 
Animal treatment 
Tamoxifen (Sigma Chemical Co., St. Louis, MO) 
was dissolved in corn oil at 20 mg/ml. Mice were 
treated with tamoxifen (100 mg/kg/day, i.p.) for five 
consecutive days for inducible activation of the β-gal 
reporter expression. In some experiments, mice were 
castrated at 8 weeks of age, treated with tamoxifen at 
10 weeks of age and then with a testosterone pellet (5 
mg/pellet in Beeswax, Sigma) at 12 weeks of age, 
followed by a replacement of the pellet with a fresh 
one at 14 weeks of age. Their prostates were examined 
at 13 and 16 weeks of ages. 
X-gal staining and immunofluorescence 
For X-gal staining, prostate tissue was fixed with 
2% (w/v) paraformaldehyde (PFA) for 1 hour, 
washed with PBS for 1 hour, incubated in an incuba-
tion buffer for 1 hour, and then incubated with 
X-gal-staining solution for 16 hours at room temper-
ature. The stained tissue was dehydrated, paraf-
fin-embedded, sectioned and counter-stained with 
Nuclear Fast Red. For immunofluorescence, rehy-
drated prostate tissue was boiled in a citrate buffer 
(pH 6.0) for antigen retrieval, treated with 3% hydro-
gen peroxide for inactivating endogenous peroxidase, 
washed with PBS containing 0.05% Tween-20, and 
blocked with 5% normal goat serum for 2 hours. For 
double immunofluorescent staining, the blocked tis-
sue slides were incubated with the antibody against 
K5 (rabbit polyclonal, Covance, Princeton, NJ), K8 (rat 
monoclonal, Developmental Studies Hybridoma 
Bank, Iowa City, IA) or Syp (rabbit polyclonal, Invi-
trogen, Camarillo, CA) overnight at 4oC, and with an 
appropriate fluorescence-labeled (Invitrogen) or bio-
tinylated (Jackson ImmunoResearch Lab, West Grove, 
PA) secondary antibody for 1 hour at room tempera-
ture. Signals were amplified with the TSA-Alexa Fluor 
488 kit (Invitrogen). Then, the tissue slides were in-
cubated with the anti-β-gal antibody (chicken poly-
clonal, Abcam, Cambridge, MA) overnight at 4oC and 
the biotinylated secondary antibody for 1 hour at 
room temperature. Signals were amplified with the 
TSA-Alexa Fluor 594 kit (Invitrogen). For Triple im-
munofluorescent staining, the blocked tissue slides 
were incubated with antibodies against p63 (mouse 
monoclonal, Santa Cruz Biotechnology, Santa Cruz, 
CA), K14 (chicken polyclonal, Covance, Princeton, NJ) 
and K5 (rabbit polyclonal, Covance) overnight at 4oC, 
and the biotinylated secondary antibodies for 1 hour 
at room temperature. Signals were amplified with the 
TSA-kit (Invitrogen). The Alexa-Fluor dyes used for 
p63, K5 and K14 were 594, 488 and 680, respectively. 
Results 
K14, K5 and p63 triple immunofluorescent 
staining identified seven subtypes of BCs 
including the subtype of p63+/K14-/K5- BCs. 
It has been reported that LECs in adult mice are 
rarely derived from tamoxifen-inducible 
K14-CreERT2-marked BCs and also very inefficiently 
derived from tamoxifen-inducible K5-CreERT2- 
marked BCs [8-10]. The discrepancy between these 
reports and the previous indirect evidence supporting 
the stem cells within the basal layer in adult mice [15] 
suggests a possible existence of K14-/K5- stem cells 
within the basal layer. To examine BC heterogeneity, 
we analyzed the co-expression patterns of the p63, 
K14 and K5 BC markers in the mouse prostate sec-
tions by triple immunofluorescent staining. Interest-
ingly, we identified seven subtypes of BCs with dif-
ferent percentages in cell number, including 
p63+/K14-/K5- (3.2%), p63-/K14-/K5+ (5.6%), 
p63+/K14-/K5+ (4.0%), p63-/K14+/K5- (1.6%), 
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p63+/K14+/K5- (9.6%), p63-/K14+/K5+ (14.6%) and 
p63+/K14+/K5+ (61.4%) BCs (Fig. 2). These results 
indicate that individual BCs are heterogeneous and 
express different BC markers and that different BC 
subpopulations may have different structural and 
functional contributions to normal and cancerous 
prostates. 
The p63+ BCs in adult prostate contain 
epithelial stem cells. 
Identification of the previously unknown BC 
subpopulations provoked our interest in testing 
whether the p63+/K14-/K5- BC subpopulation con-
tains multi-potent stem cells in the murine prostate. 
This subpopulation has not yet been tested in previ-
ous studies tracing the K5+ or K14+ BC lineages. To 
examine the lineage fate of the p63+ BCs, we con-
structed a knock-in vector, inserted the 
CreERT2-coding DNA for the tamoxifen-inducible 
Cre recombinase into the fourth exon of the p63 gene 
in the mouse embryonic stem (ES) cells, and generat-
ed p63-CreERT2 mice from the targeted ES cells (Fig. 
1). We crossed p63-CreERT2 mice with Rosa26R mice 
harboring a Cre-activated expression of the β-gal re-
porter [14] and generated p63-CreERT2×Rosa26R 
bi-genic mice. In these bi-genic mice, the CreERT2 
fusion protein expressed in p63+ BCs and remained 
inactive in the cytoplasm and thus, the β-gal reporter 
was silent before tamoxifen treatment. 
 
 
Figure 2. Identification of seven subtypes of BCs in the adult mouse prostate by triple immunofluorescent staining of p63, K5 and K14. Triple immunofluorescent staining was 
performed on prostate sections prepared from three 6-week-old mice. Immunofluorescent staining signals of p63, K5 and K14 were separately imaged by using appropriate filters 
and a monochrome CCD camera and respectively labeled as red, green and white colors. Each of the three bottom panels is the merged image of the three panels above plus the 
blue DAPI staining signal for nuclei. The 7 BC subtypes were distinguished according to the expression patterns of p63, K5 and K14 as indicated. The percentage of each subtype 
BCs was calculated by normalizing to the total number of counted BCs. 
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To examine whether p63+ BCs contain epithelial 
stem-like cells in the developed prostate, we treated 
4-week-old p63-CreERT2×Rosa26R mice with tamox-
ifen for 5 days to activate β-gal expression in the p63+ 
BCs. We confirmed that only a proportion of BCs but 
no LECs were positive to X-gal staining in one week 
after tamoxifen treatment (Fig. 3A and B). At this time 
point, we isolated prostate epithelial cells and per-
formed epithelial sphere formation assay in Matrigel 
culture. From the initial culture, about 200 spheres in 
average were developed from epithelial cells isolated 
from each mouse. About 48% and 52% of these 
spheres composed of β-gal-negative (β-gal-) and 
β-gal-positive (β-gal+) cells, respectively (Fig. 3A and 
C). The β-gal+ spheres were derived from the 
p63-CreERT2-marked BCs. We subsequently digested 
all spheres into single cell suspension and re-cultured 
these cells for developing the second generation of 
spheres, followed by serial passages of third and 
fourth generations of sphere formation assays. We 
found that about 30% of the spheres composed of only 
β-gal+ cells throughout these passages (Fig. 3A). The 
lower percentage of β-gal+ spheres in the second 
generation versus the first generation suggests that 
some initial β-gal+ spheres were developed from par-
tially differentiated, non-self-renewable intermediate 
p63+ BCs. We also isolated prostate epithelial cells 
from 6-week-old mice without tamoxifen treatment 
and allowed them form epithelial spheres in culture 
(Fig. 3A). After a brief tamoxifen treatment in culture, 
one to several cells in a sphere were stained blue by 
X-gal staining (Fig. 3D), suggesting that these were 
p63+ cells in these spheres. After the cells of these 
spheres were assayed in serial passages, we again 
identified a constant ratio of 13-14% blue spheres 
throughout the subsequent passages (Fig. 3A and E). 
These results clearly indicate that the p63+ BCs in the 
adult mouse prostate contain self-renewable stem-like 
cells. 
The p63-expressing BCs contain pluripotent 
stem-like cells during postnatal prostate 
morphogenesis. 
To trace the lineage differentiation of the 
p63-expressing BCs during postnatal development, 
we treated 2-week-old p63-CreERT2×Rosa26R mice 
with tamoxifen, collected prostates 1 and 4 weeks 
after tamoxifen treatment, and performed X-gal 
staining (Fig. 4A). One week after tamoxifen admin-
istration, X-gal staining signal was only observed in 
BCs (Fig. 4B). Double immunofluorescent staining 
revealed that 27.6% of K5+ BCs were also β-gal posi-
tive (Fig. 4D and G), while no β-gal+/K8+ LECs and 
β-gal+/Syp+ neuroendocrine cells (NECs) were ob-
served at this time point (Fig. 4E and G, and data not 
shown). 
 
 
Figure 3. The p63+ BCs in the developed mouse prostate contain epithelial stem-like cells. A. Experimental flowchart. Three mice were used for each experiment 
(n=3). G1–G4 indicate sphere generations 1–4. The percentages of blue spheres (BSs), which are the β-gal+ spheres derived from the marked p63+ BCs, are indicated. B. 
X-gal-stained prostate tissues prepared from vehicle or tamoxifen-treated p63-CreERT2×Rosa26R mice. C. X-gal-stained epithelial spheres formed from isolated prostate 
epithelial cells of tamoxifen-treated p63-CreERT2×Rosa26R mice. White (WS) and blue (BS) spheres are indicated. D. A tamoxifen-treated epithelial sphere developed from the 
isolated prostate epithelial cells of untreated p63-CreERT2×Rosa26R mice. E. A blue second-generation sphere developed from re-culturing cells of the tamoxifen-treated 
first-generation spheres. 
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Figure 4. LECs, BCs and NECs developed from p63+ BCs during postnatal prostate morphogenesis. A. Schematic of the lineage tracing experiment during 
postnatal prostate development of p63-CreERT2×Rosa26R mice. B and C. X-gal-stained prostate tissues at 3 and 6 weeks of age. The blue signal indicates β-gal-expressing cells 
in basal (panel B) and in both basal and luminal layers (panel C). D and E. Unmerged and merged images of double immunofluorescent staining for β-gal and K5 (panel D) and for 
β-gal and K8 (panel E) on prostate sections at 1 and 4 weeks after tamoxifen treatment. Arrowheads indicate double positive cells. Asterisks indicate a β-gal+/K5- LEC in panel 
D and a β-gal+/K8- BC in panel E. F. Unmerged and merged images of double immunofluorescent staining for β-gal and Syp on prostate sections at 4 weeks after tamoxifen 
treatment. The arrowhead indicates a β-gal+/Syp+ NEC, which is rare in number. Asterisks indicate two β-gal+/Syp- BCs and one LEC. G. The percentage of β-gal+/K8+ to total 
K8+ cells and the percentage of β-gal+/K5+ cells to total K5+ cells at 3 and 6 weeks of ages. 
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However, 4 weeks after tamoxifen treatment, 
β-gal+ LECs were clearly detected (Fig. 4C). Double 
immunofluoresence staining identified 48.3% of K5+ 
BCs, 17.8% of K8+ LECs, and certain Syp+ NECs as 
β-gal+ cells in the prostates of p63-CreERT2×Rosa26R 
mice (Fig. 4D–G, and data not shown). These results 
indicate that the p63-expressing BCs in the prostate of 
2-week-old mouse contain pluripotent stem-like cells 
that can generate LECs, BCs and NECs at the postna-
tal stage of prostate morphogenesis. One previous 
study also showed that isolated p63+ BCs could gen-
erate other types of prostate epithelial cells in vitro 
[16], while another study used a non-inducible mouse 
model to follow the fate of p63+ cells since embryo 
development and suggested p63+ cells as the prostate 
progenitor cells [17]. Together, these findings support 
the claim that p63+ BCs contain epithelial stem cells 
during postnatal morphogenesis of the prostate. In-
terestingly, the K14+ BCs were also shown to be able 
to develop into all types of prostate epithelial cells at 
this early postnatal developmental stage of prostate 
although these cells were unable to do so in adult-
hood [8, 9], suggesting that the stem cell population at 
this stage is different from that in the adult prostate. 
The p63-expressing BCs generate LECs, BCs 
and NECs during maintenance of the epithelial 
homeostasis of the prostate in adult mouse. 
Identification of stem cells in the adult prostate is 
extremely valuable because these cells may serve as 
prostate cancer-initiating cells in the adult prostate. 
To investigate whether p63+ BCs in the adult prostate 
contain epithelial stem cells, we treated 8-week-old 
p63-CreERT2×Rosa26R mice with tamoxifen to mark 
BCs with β-gal expression and assessed β-gal+ cell 
types by X-gal staining and double immunofluores-
cent staining 1 or 4 weeks after tamoxifen treatment 
(Fig. 5A). At the 1-week time point, all β-gal+ cells 
were located in the basal layer (Fig. 5B). Most of the-
se β-gal+ cells were K5+ BCs, but none of these β-gal+ 
cells were K8+ LECs or Syp+ NECs (Fig. 5D and E, 
and data not shown). However, at the 4-week time 
point, β-gal+ LECs cells were clearly observed (Fig. 
5C). Double immunofluorescent staining not only 
identified gal+/K5+ BCs but also identified 
β-gal+/K8+ LECs as well as the gal+/Syp+ NECs 
(Fig. 5D–F). These results demonstrate, for the first 
time, that p63+ BCs in the adult prostate can generate 
all three types of prostatic epithelial cells including 
the rare NECs. 
To determine the dynamic contributions of the 
p63+ BCs to the prostate epithelial homeostasis over a 
long period of time, we treated young adult 
p63-CreERT2×Rosa26R mice with tamoxifen for 7 
days (2 days longer than other experiments to en-
hance efficiency), and isolated their prostates for X-gal 
staining at 4, 8, 12 and 20 weeks after tamoxifen 
treatment. Interestingly, about 80-85% of BCs were 
stained positive to β-gal expression throughout all 
time points, suggesting that these p63+ BCs maintain 
their homeostasis through self-renewal. More strik-
ingly, the percentages of β-gal+ LECs were progres-
sively increased from 2% at the 4th week to 43% at the 
20th week after tamoxifen treatment (Fig. 5G). These 
results demonstrate, for the first time, that the p63+ 
BCs in the adult mouse prostate can efficiently gener-
ate new LECs to maintain the prostate epithelial ho-
meostasis. 
The p63-expressing BCs efficiently produce 
LECs and NECs during prostate regeneration. 
In the castration-testosterone (T) replacement 
mouse model, the prostate epithelium experiences a 
highly dynamic remodeling process involving apop-
tosis, proliferation and differentiation, making it an 
ideal model for tracing BC differentiation into other 
types of epithelial cells. We castrated 8-week-old 
p63-CreERT2×Rosa26R mice, then treated these mice 
with tamoxifen for 5 days at 10 weeks of age, and 
subsequently with T from 12 to 16 weeks of age (Fig. 
6A). In the prostates of castrated mice before and after 
T treatment for one week, β-gal expression was only 
observed in BCs (Fig. 6B and C). However, after T 
treatment for 4 weeks, β-gal expression was detected 
in many of both BCs and LECs (Fig. 6D). Double im-
munofluorescent staining confirmed that β-gal+/K5+ 
BCs but no β-gal+/K8+ LECs were observed at the 
time points before or after T treatment for one week 
(Fig. 6E and F, and data now shown). After T treat-
ment for 4 weeks, both β-gal+/K5+ BCs and 
β-gal+/K8+ LECs were observed (Fig. 6E and F). 
Quantitative analysis revealed that the percentage of 
β-gal+/K5+ BCs versus total BCs was significantly 
increased over time upon T treatment, while a signif-
icant percentage of p63+/K8+ LECs were only de-
tected after 4 weeks of T treatment (Fig. 6G). Inter-
estingly, the β-gal+/Syp+ NECs were observed both 
before and after T treatment for 1 and 4 weeks (Fig. 7), 
suggesting an androgen-independent differentiation 
process from BCs to NECs in the adult prostate. These 
results demonstrate that p63+ BC population contains 
stem cells that can differentiate into all three types of 
prostate epithelial cells during prostate regeneration 
in response to T stimulation. 
 
 
Int. J. Biol. Sci. 2014, Vol. 10 
 
 
http://www.ijbs.com 
1014 
 
Figure 5. p63+ BC differentiation into BCs, LECs and NECs in adult prostates. A. Schematic of the lineage tracing experiments during prostate homeostasis in the 
adult p63-CreERT2×Rosa26R mice. B and C. X-gal-stained prostate tissues at 9 and 12 weeks of age. The blue signal indicates β-gal+ cells in basal (panel B) and in both basal and 
luminal (panel C) layers. D and E. Unmerged and merged images of double immunofluoresent staining for β-gal and K5 or K8 on the prostatic sections from mice at weeks 1 and 
4 after tamoxifen treatment. Arrowheads indicate double positive cells. F. Unmerged and merged images of double immunofluorescent staining for β-gal and Syp on the prostatic 
sections from mice at weeks 1 and 4 after tamoxifen treatment. The arrowhead indicates a double positive NEC. G. The percentage of β-gal+ BCs to total BCs and the 
percentage of β-gal+ LECs to total LECs at the indicated ages of p63-CreERT2×Rosa26R mice. Enhanced tamoxifen treatment was administrated to 4-week-old mice and prostate 
X-gal staining was performed at 8, 12, 16 and 24 weeks of ages. Data were obtained from 3 mice at each age point. 
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Figure 6. Differentiation of β-gal-labeled p63+ BCs into BCs and LECs during prostate regeneration. A. Schematic of the lineage tracing analysis during testos-
terone (T)-stimulated prostate regeneration in castrated CreERT2×Rosa26R mice. Cas, castration; wk, mouse ages in weeks. B–D. X-gal staining (blue) of prostate tissues at 12, 
13 and 16 weeks of age, respectively. E. Unmerged and merged images of double fluorescent staining for β-Gal and K5 on the prostate sections from mice without T treatment 
(0 wk with T) and with T treatment for 1 and 4 weeks. Note the increased number of β-gal+/K5+ BCs at 1 week of T treatment versus that at 0 week of T treatment, which 
suggests new BCs derived from previous BCs. The arrowhead indicates β-gal+/K5- LECs. F. Unmerged and merged images of double fluorescent staining for β-gal and K8 on the 
prostate sections from mice with T treatment for 1 and 4 weeks. The arrowhead indicates the β-gal+/K8+ LECs. G. Percentages of β-gal+/K8+ to total K8+ cells and β-gal+/K5+ 
to total K5+ cells at 12, 13 and 16 weeks of ages as indicated in panel A.  
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Figure 7. Androgen-independent differentiation of p63+ BCs into NECs during prostate regression and regeneration. The p63-CreERT2×Rosa26R mice were castrated at 8 
weeks of age and treated with tamoxifen at 10 weeks of age and with T from 12 to 16 weeks of age (refer to Fig. 6A). Double immunofluorescent staining for β-gal and Syp were 
performed on the prostate sections from mice without T treatment at 12 weeks of age (0 week with T) and with T treatment for 1 and 4 weeks as indicated. 
 
Discussion 
A great effort has been devoted to identify stem 
cells in the prostatic epithelium because of their rele-
vance to postnatal morphogenesis, and adult epithe-
lial homeostasis and carcinogenesis. Initial studies 
using in vitro and ex vivo models showed that the ep-
ithelial cells, especially, the basal cell population in 
the adult prostate contain multipotent stem cells [16]. 
However, several recent in vivo studies reported con-
troversial results regarding the identities of these stem 
cells in the basal cell layer. Ousset et al. demonstrated 
that the K14+ BCs marked at two weeks of age could 
efficiently differentiate into other types of epithelial 
cells [8], which is consistent with our results from 
tracing the p63+ BCs at the same stage. In contrast to 
the stage of postnatal development, Choi et al. 
showed that the K14+ BCs marked at five weeks of 
age only produced BCs but not LECs and NECs in the 
prostate [9], suggesting that the K14+ BCs in the adult 
prostate are not stem cells. Lu et al. labeled the K5+ 
BCs in the mouse prostate at 5-6 weeks of age and 
observed that only 2% of LECs were derived from the 
labeled K5+ BCs after 17 weeks [18]. Furthermore, 
Wang et al. marked the K5+ BCs in 8-week-old adult 
mice, and found that almost no marked LEC was 
generated from these BCs under normal physiological 
condition, only 0.03% of marked LECs were generated 
from these BCs after one regression-regeneration cy-
cle, and only 3.4% of marked LECs were generated 
even after five regression-regeneration cycles [10]. 
Given the inefficient differentiation and the 
age-dependent reduction of differentiation efficiency 
from the K5+ BCs to LECs, the K5+ BCs are unlikely 
the majority of stem cells in the adult prostate. In rel-
evance to the K5+ BC-tracing model, another previous 
study showed the castration-resistant 
Nkx3.1-expressing LECs (CARNs) could generate 
some of the LECs, BCs and NECs in the regres-
sion-regeneration cycles [19]. It is possible that the 
marked K5+ BCs in the adult prostate are intermedi-
ate progenitor cells, which become some of the 
CARNs and subsequently differentiate into other 
types of epithelial cells during the regres-
sion-regeneration cycles. Intermediate progenitor 
cells express relatively low levels of both BC markers 
such as K5 and K14 and LEC markers such as K8 and 
K18. These intermediate cells have been considered as 
differentiating cells from BC compartment to LEC 
compartment many years ago [20-22]. 
Our results support the idea that the marked 
p63+ BCs efficiently differentiate into all of the three 
types of epithelial cells including LECs, BCs and 
NECs in the developing, adult and regenerating 
prostates. In comparison with previous studies, our 
study demonstrates, for the first time, that the p63+ 
BCs can generate NECs and can very efficiently de-
velop into LECs in the adult prostate. The identifica-
tion of the seven BC subpopulations by the different 
expression fingerprints of p63, K5 and K14 should 
help to explain the discrepancies among the genetic 
models tracing the K14+, K5+ or p63+ BC lineage. We 
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found that 96.8% of total BCs and 96.0% of p63+ BCs 
express K14 and/or K5, indicating the majority of BCs 
or p63+ BCs are not stem cells in the adult prostate 
based on the reported lineage-tracing data from trac-
ing the K14+ and the K5+ BCs [8, 9, 19]. Importantly, 
we identified a small BC subpopulation (~3.2%) that 
only expresses p63 but not K14 and K5. This finding 
suggests that the marked p63+ BCs include a unique 
BC subpopulation that has never been linage-traced 
previously and may be responsible for the major 
origin of LECs, NECs and BCs in the adult prostate. 
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